louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01404858: The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome
Official title: The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Keywords: IVF
Lifestyle habits
Lead sponsor: Boston IVF
Sponsor class: OTHER
First posted: 2011-07-28
Enrollment: 12800
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and women undergoing IVF at a infertility clinic who uses eIVF, an electronic medical record collection entity specifically for IVF patients

Brief summary: The purpose of this study is to prospectively examine the impact of various lifestyle habits in both men and women on the outcome of in vitro fertilization. There are 25 infertility centers in the United States which use the electronic medical record collection entity eIVF, made by Practice Highway, to collect medical and demographic information on the patients who are undergoing treatment at these centers. Information on every aspect of each cycle is also electronically collected daily during each cycle. Demographic and lifestyle information will be collected on all patients prior to cycle start and lifestyle habit information will be collected each time a patient logs onto the patient portal, which averages every few days.


Eligibility criteria: Inclusion Criteria:

Eligible patients include, any patient whose:

* infertility clinic uses eIVF
* is scheduled to undergo an IVF cycle
* has access to the internet on a daily basis
* can read and understand English
* logs onto the patient portal on eIVF

Primary outcomes:
measure: Clinical Pregnancy Rates
timeFrame: Approximately 28 days (1 IVF cycle)
Secondary outcomes:
Other outcomes:
Locations:
city: Waltham
country: United States
facility: Boston IVF
state: Massachusetts
Study officials:
affiliation: Boston IVF
name: Alice D Domar, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04112758: Exercise Intervention on Conflict Monitoring in Children With Attention-deficit Hyperactivity Disorder
Official title: The Effect of Long-term High-intensity Interval Training on Conflict Monitoring in Children With ADHD: an ERP and sLORETA Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise Intervention
Keywords: HIIT
executive function
ADHD
chronic exercise
Lead sponsor: National Taiwan Normal University
Sponsor class: OTHER
First posted: 2019-10-02
Enrollment: 110
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study mainly investigates the effect of high-intensity interval training on conflict monitoring in children with ADHD by using event-related potential and sLORETA techniques.

Detailed description: The present study will have two experiments, one is a cross-section study and the other is intervention study.

As for cross-section study, typical developmental children and children with ADHD will perform the stroop task while recording their brain waves.

The intervention is twice a week for 5 weeks and before and after the intervention, children with ADHD will randomly assign to either an exercise group or control group. They will perform the stroop task while recording their brain waves.

Eligibility criteria: Inclusion Criteria:

1. age between 7 and 12 years
2. diagnosed with ADHD by a pediatric psychiatrist, which is not required for TD
3. no history of brain injury or neurological conditions, such as exhibited epileptic seizures, serious head injuries, and periods of unconsciousness.

Exclusion Criteria:

1. cannot follow the instruction
2. cannot complete all the procedure

Primary outcomes:
measure: Behavioral performance
timeFrame: Day 0 and post-intervention at Week 5
measure: Behavioral performance
timeFrame: Day 0 and post-intervention at Week 5
Secondary outcomes:
measure: N2 & P3 components
timeFrame: Day 0 and post-intervention at Week 5
Other outcomes:
measure: Brain activation
timeFrame: Day 0 and post-intervention at Week 5
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan Normal University
Study officials:
References:
Clinical trial NCT05234658: Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery
Official title: Phase II Clinical Trial Evaluating the Safety and Efficacy of a Tissue Engineered Autologous Skin Substitute Reconstructive Surgery for Basal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Basal Cell Carcinoma
Lead sponsor: Andalusian Network for Design and Translation of Advanced Therapies
Sponsor class: OTHER
First posted: 2022-02-10
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase II Clinical Trial Evaluating the Safety and Efficacy of a Tissue Engineered Autologous Skin Substitute Reconstructive Surgery for Basal Cell Carcinoma


Eligibility criteria: Inclusion Criteria:

1. Patients that give their informed consent for study participation.
2. Adult (18 years of age or older), of any sex and racial origin.
3. Clinical and dermatoscopic diagnosis of basal cell carcinoma with lesions on the scalp, torso or extremities, within a certain size that do not allow for surgical closure by direct suture or flaps. Namely, indication for Mohs surgery.
4. Women with childbearing age or men capable of producing a child, should commmit to use contraceptives of medically proven efficacy.

Exclusion Criteria:

1. Locally advanced basal cell carcinoma with evidence of tissue infiltration.
2. Lesions in the face.
3. Injuries requiring urgent surgical intervention.
4. Infected lesions, necrosis, scarcely vascularized injuries or other complications that may interfere with healing and/or integrity of the graft.
5. Injuries that have received treatment with radiotherapy.
6. Contraindication for Mohs surgery.
7. Known allergies to Biobrane dressing.
8. Pregnant or breastfeeding women.
9. Coexistence of any other pathology that, in the investigator's opinion, could compromise the healing process or interfere with protocol follow-up.
10. Participation in other clinical trials in 3 months previous to inclusion, or in the previous 5 years for trials with advanced therapies.

Primary outcomes:
measure: Safety of autologous bioengineered skin
timeFrame: Through study completion, an average of 2 year
measure: Efficacy of autologous bioengineered skin
timeFrame: Through study completion, an average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Marbella
country: Spain
facility: Hospital Costa del Sol
state: Málaga
city: Granada
country: Spain
facility: Hospital U. Virgen de las Nieves
city: Málaga
country: Spain
facility: Hospital U. Virgen de la Victoria
city: Sevilla
country: Spain
facility: Hospital U. Virgen Macarena
Study officials:
References:
Clinical trial NCT03175458: Schnederian Membrane Elevation and Augmentation With Deproteinized Bovine Bone [Tutu-gen Bone] Versus Graft Less Tenting Technique With Simultaneous Implant Placement
Official title: Schnederian Membrane Elevation and Augmentation With Deproteinized Bovine Bone [Tutu-gen Bone] Versus Graft Less Tenting Technique With Simultaneous Implant Placement: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Maxillary Sinus Floor Elevation
Keywords: tenting
grafting
implant placement
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-06-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 30 recruited patients indicated for sinus membrane elevation with simultaneous implant placement. patients are divided into 2 groups each group contain 15 patients, one group assigned for placement of bovine bone graft after membrane elevation and insertion of the implants while the other group assigned for graft-less tenting technique after membrane elevation and insertion of the implant.

Detailed description: On the 2 groups a mucoperiosteal flap is elvated then a lateral wondow is created then sinus membrane is elevated then the implants are placed, in the control group deproteinized bovine bone graft substitute is placed in the sinus for augmentation while in the study group no bone graft is added inside the sinus( graftless tenting technique)

Eligibility criteria: Inclusion Criteria:

* patients with atrophic maxilla and pneumatization of the maxillary sinus with residual bone height at least 5mm as per MISCH criteria.
* both sexes.

Exclusion Criteria:

* sinus pathology
* heavy smokers(more than 20 cigarettes per day.
* patients with systemic disease that may affect normal healing.

Primary outcomes:
measure: patient satisfaction
timeFrame: 7 days post operative
Secondary outcomes:
measure: implant stability
timeFrame: will be measured intraoperatively immediately after insertion of the implants and will be measure one more time 6 months after the 1st operation at the time of exposure of the implants
measure: height of bone gained or lost around the implants
timeFrame: 6 months postoperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry Cairo University
Study officials:
References:
Clinical trial NCT06769958: The Effect of Reflexology on Pain, Comfort and Breastfeeding Self-Efficacy
Official title: The Effect of Reflexology on Pain, Comfort and Breastfeeding Self-Efficacy in Post-Cesarean Headache Due to Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reflexology
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2025-01-10
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study was conducted to determine the effects of reflexology applied to mothers with headache due to spinal anesthesia after Cesarean delivery on pain, comfort and breastfeeding self-efficacy levels. The study, which was conducted with a single-blind, randomized controlled experimental design, was conducted between April 2024 and August 2024 at the Department of Obstetrics and Pediatrics, SBU Van Training and Research Hospital with mothers who had cesarean delivery under spinal anesthesia and had postpartum headache (Intervention group=30, Control group=30). Foot reflexology was applied to the mothers in the intervention group for a total of 30 minutes, 15 minutes on each foot. The control group was not subjected to any intervention other than routine nursing practices. Personal Information Form, Visual Analog Scale (VAS), Postpartum Comfort Scale (PPSC) and Breastfeeding Self-Efficacy Scale (BSSE) were used as data collection tools.


Eligibility criteria: Inclusion Criteria:

* 18 years and older,
* performing SD under spinal anesthesia,
* experiencing postpartum headaches,
* Caesarean section performed at 37-42 weeks of gestation,
* giving only one live birth,
* open to written or oral communication,
* at least a primary school graduate,
* no complications during pregnancy,
* mothers who agreed to participate in the study

Exclusion Criteria:

* Performing a cesarean section at periods other than 37-42 weeks of gestation,
* caesarean section under general anesthesia,
* have health problems such as fractures, dislocations, phlebitis, arthritis, burns, wounds, eczema, fungus or inflammation in the foot tissue,
* with disease of the cardiovascular system,
* with chronic diseases such as hypertension or diabetes mellitus,
* Postpartum controlled analgesia administered,
* mothers with psychiatric diagnoses such as anxiety and depression

Primary outcomes:
measure: Visual Analog Scale
timeFrame: pre-test post-test (approximately eight months), reduce pain
measure: Postpartum Comfort Scale
timeFrame: pre-test post-test (approximately eight months), Increasing Postpartum Comfort
measure: Breastfeeding Self-Efficacy Scale
timeFrame: pre-test post-test (approximately eight months), Increasing breastfeeding self-efficacy
Secondary outcomes:
Other outcomes:
Locations:
city: VAN
country: Turkey
facility: Van Yüzüncü Yıl University
state: Tuşba
Study officials:
References:
Clinical trial NCT00945958: Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open Angle Glaucoma
Ocular Hypertension
Keywords: Glaucoma
Ocular hypertension
Lead sponsor: Sun Pharma Advanced Research Company Limited
Sponsor class: INDUSTRY
First posted: 2009-07-24
Enrollment: 161
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.

Detailed description: This is a multicenter, open label, non-randomized, single-arm, extension safety study to evaluate the long-term safety of SPARC0913. Subjects who completed the prior evaluator-masked clinical non-inferiority Study participated in the current study.

Eligibility criteria: Inclusion Criteria:

* Men and women aged ≥18 years
* Willing to participate and giving written informed consent
* Willing to commit to study medication-dosing, study visits and follow-up visits to complete evaluation
* Eligible to receive Latanoprost once a daily as monotherapy for treatment of glaucoma

Exclusion Criteria:

* History of allergic hypersensitivity or poor tolerance to latanoprost
* History of Substance abuse or addiction (alcohol drugs) in the past 3 years
* History of chronic use of concomitant medications in neurologic or psychiatric illness that would affect assessment of safety and effectiveness of the study medication
* Any abnormality preventing IOP measurement

Primary outcomes:
measure: Number of Subjects With AEs
timeFrame: 24 weeks
Secondary outcomes:
measure: Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)
timeFrame: 24 weeks
Other outcomes:
Locations:
city: High Point
country: United States
facility: SPARC study site
state: North Carolina
Study officials:
References:
citation: Shen Lee B, Malhotra R, Sall K, Mitchell B, Peace J. Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension. Clin Ophthalmol. 2022 Jul 19;16:2285-2293. doi: 10.2147/OPTH.S367756. eCollection 2022.
Clinical trial NCT03239158: Bioinformation Therapy for Liver Cancer
Official title: Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Liver Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Liver, Cancer of, Non-Resectable
Keywords: Cancer ablation
Life information rehabilitation therapy
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
Collaborators: name: Shengxin Biotechnology Institute, Beijing
First posted: 2017-08-03
Enrollment: 120
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.

Detailed description: By enrolling patients with unresectable liver cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility criteria: Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies
* Body tumor 1-6, with at least one tumor length \> 2 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Primary outcomes:
measure: Relief degree of tumors
timeFrame: 3 months
Secondary outcomes:
measure: Progress free survival（PFS）
timeFrame: 1 year
measure: Overall survival（OS）
timeFrame: 3 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Fuda cancer institute of Fuda cancer hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT06144658: VR-MARS Virtual Reality, Medical Assistance and Rescue for Space
Official title: VR-MARS Virtual Reality, Medical Assistance and Rescue for Space
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Instructional Virtual Realities
Weightlessness Simulation
Space Simulation
Patient Simulation
High Fidelity Simulation Training
Lead sponsor: Groupe Hospitalier de Bretagne Sud
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: VRMARS is a medical simulation study in microgravity. Healthy volunteers (n=18) test in microgravity the functionnality of an augmented reality headset in which a medical assistance is displayed.


Eligibility criteria: Inclusion Criteria:

Healthy male or female volunteers.

* Aged between 18 and 66.
* Not currently pregnant.
* Affiliated to a social security system or, for non-Europeans, holders of a European Health Insurance Card (EHIC).
* Have signed written consent for the study.
* Have passed a standard JAR FCL3 Class 2 (Private Pilot Aptitude) medical examination less than 1 year old.

Exclusion Criteria:

On the day of the flight, before the volunteer boards the plane:

* Flu, digestive symptoms (nausea, vomiting), fever.
* Pregnancy: a urine pregnancy test will be performed on the morning of the flight before boarding.
* Altered mental state (flight anxiety, phobia).
* Failure to attend the safety briefing.

During the flight :

* Non-compliance with basic safety instructions.
* Flight-related side effects: fatigue, motion sickness.

Primary outcomes:
measure: Technical validation of the headset in microgravity
timeFrame: 1 day
measure: Usability test HARUS / Form
timeFrame: 1 day
measure: NASA-TLX cognitive test
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Lorient
country: France
facility: Groupe Hospitalier de Bretagne Sud
Study officials:
References:
Clinical trial NCT03933358: Effect of Thyroid Hormone on Post-Myocardial Infarction Remodeling and Prognosis in STEMI Patients
Official title: Effect of Thyroid Hormone on Post-Myocardial Infarction Remodeling and Prognosis in STEMI Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroid
Cardiac Remodeling, Ventricular
STEMI
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2019-05-01
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to Beijing Friendship Hospital with a confirmed STEMI diagnosis undergoing primary percutaneous coronary intervention

Brief summary: This study aims to determine whether thyroid hormone levels are predictive of cardiac remodeling following myocardial infarction and the prognosis in patients with STEMI receiving primary percutaneous coronary intervention.


Eligibility criteria: Inclusion Criteria:

* with a confirmed STEMI diagnosis
* undergoing primary percutaneous coronary intervention (presenting \<12h after symptom onset)
* patients agreed and provided informed consent

Exclusion Criteria:

* past history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass graft
* past history of heart failure (LVEF\<40%) or myocardiopathy or atrial fibrillation
* past history of thyroid diseases, or were treated with amiodarone, dopamine, or corticosteroids before hospital admission
* contraindicating to cardiac magnetic resonance imaging

Primary outcomes:
measure: MACE (major adverse cardiovascular events)
timeFrame: 12 months
Secondary outcomes:
measure: adverse cardiac remodeling
timeFrame: 6 months
measure: all-cause death
timeFrame: 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University
Study officials:
References:
Clinical trial NCT02780258: Restylane Silk for Photoaged Thinned Hands
Official title: Restylane Silk for Photoaged Thinned Hands
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Photoaged Thinning of the Hands
Lead sponsor: Skin Laser & Surgery Specialists
Sponsor class: OTHER
First posted: 2016-05-23
Enrollment: 25
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of Restylane Silk for photoaged thinned hands


Eligibility criteria: Inclusion Criteria:

* Female volunteer
* Aged from 40-70 years on the day of screening
* No known medical conditions that may interfere with study participation
* Moderate to very severe Photoaged thinning of the hands based on the 5-point hand grading scale
* Willingness to not use any products on their hands for the duration of the study
* Read, understand, and sign informed consent forms
* Willingness to sign photography release form
* Willing and able to comply with all follow-up requirements
* Willingness to undergo Restylane Silk injections to one hand

Exclusion Criteria:

* Any significant skin disease at treatment area
* Any medical condition which could interfere with the treatment
* Inability or unwillingness to follow the treatment schedule
* Inability or unwillingness to sign the informed consent
* History of poor wound healing
* History of keloid formation
* History of HIV, hepatitis, immuno-compromised
* Pregnant or lactating
* Previous use of deep chemical peels on the treatment area
* Previous injections of Restylane Silk to the hands
* Known hypersensitivity to Restylane Silk or any of its ingredients
* Previous laser or light based treatments to the treatment area 6 months prior to the screening visit

Primary outcomes:
measure: Change in photoaged thinning of the treatment area as measured by the 5 point hand grading scale
timeFrame: Baseline, 1month, 3months, 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: